We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Grape Seed Extract Kills Head and Neck Cancer Cells

By LabMedica International staff writers
Posted on 07 Feb 2012
New research shows that in both cell lines and mouse models, grape seed extract (GSE) kills head and neck squamous cell carcinoma cells, while leaving healthy cells unharmed.

The research findings were published January 2012 in the journal Carcinogenesis. “It’s a rather dramatic effect,” stated Rajesh Agarwal, PhD, investigator from the University of Colorado (Denver, USA) Cancer Center and professor at the Skaggs School of Pharmaceutical Sciences (San Diego, CA, USA). It depends mostly, according to Dr. Agarwal, on a healthy cell’s ability to outlast the damage. “Cancer cells are fast-growing cells,” he noted. “Not only that, but they are necessarily fast growing. When conditions exist in which they can’t grow, they die.”

Grape seed extract creates the conditions that are unfavorable to growth. Specifically, the study’s findings reveals that grape seed extract both damages cancer cells’ DNA (via increased reactive oxygen species) and blocks the pathways that allow repair (as evidenced by decreased levels of the DNA repair molecules Brca1 and Rad51 and DNA repair foci). “Yet we saw absolutely no toxicity to the mice, themselves,” Dr. Agarwal stated.

Once more, the grape seed extract killed the cancer cells but not the healthy cells. “I think the whole point is that cancer cells have a lot of defective pathways and they are very vulnerable if you target those pathways. The same is not true of healthy cells,” Dr. Agarwal said. The scientists hope to move in the direction of clinical trials of grape seed extract, potentially as an addition to second-line therapies that target head and neck squamous cell carcinoma that has failed a first treatment.

Related Links:

University of Colorado




Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
Thyroid Test
Anti-Thyroid EIA Test
Immunofluorescence Analyzer
IFA System

Latest BioResearch News

D-Serine May Predict Immune Checkpoint Therapy Resistance in Gastric Cancer
07 Feb 2012  |   BioResearch

New Genetic Cause Identified for Neurodevelopmental Disorder
07 Feb 2012  |   BioResearch

New Genetic Discovery Could Support Precision Diabetes Care
07 Feb 2012  |   BioResearch